Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported option exercises and related share sales. He exercised a stock option for 2,500 shares of common stock at $14.50 per share through a derivative conversion. On the same date, he sold a total of 2,500 shares of common stock in open-market transactions at weighted average prices of $40.56 and $41.66 per share under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly held 97,994 shares of common stock, which the filing notes include 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The stock option originally covered 404,857 shares, with vesting over several years.

Insider Trade Summary

Net Seller: 2,500 shares ($101,620)

Net Sell 4 txns

Insider Burrows Scott L

Role Chief Financial Officer

Sold 2,500 shs ($102K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$14.50	$36K
Sale	Common Stock	2,300	$40.56	$93K
Sale	Common Stock	200	$41.66	$8K

Holdings After Transaction: Stock Option (Right to Buy) — 402,357 shares (Direct); Common Stock — 100,494 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 09:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		M⁽¹⁾		2,500	A	$14.5	100,494	D
Common Stock	03/03/2026		S⁽¹⁾		2,300	D	$40.56⁽²⁾	98,194	D
Common Stock	03/03/2026		S⁽¹⁾		200	D	$41.66⁽³⁾	97,994⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.5	03/03/2026		M⁽¹⁾			2,500	⁽⁵⁾	09/01/2033	Common Stock	2,500	$0	402,357	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?

Spyre Therapeutics CFO Scott L. Burrows exercised options for 2,500 shares and sold 2,500 shares. The sales were open-market trades on March 3, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted November 10, 2025, according to the Form 4.

How many Spyre Therapeutics (SYRE) shares did the CFO sell and at what prices?

The CFO sold 2,500 shares of Spyre Therapeutics common stock. He executed two open-market sale transactions: 2,300 shares at a weighted average price of $40.56 and 200 shares at a weighted average price of $41.66, with individual trades ranging within stated price bands.

What stock options did the Spyre Therapeutics (SYRE) CFO exercise?

The CFO exercised a stock option covering 2,500 shares of common stock. This came from an option originally representing rights to purchase 404,857 shares, vesting over several years following a one-quarter vesting date of September 1, 2024, subject to continued employment.

How many Spyre Therapeutics (SYRE) shares does the CFO hold after these transactions?

After the reported trades, the CFO directly holds 97,994 shares of common stock. The filing specifies that this figure includes 67,476 restricted stock units, each representing a contingent right to receive one share of common stock upon future vesting milestones.

What are the vesting terms for the Spyre Therapeutics (SYRE) CFO’s RSUs?

The CFO holds 67,476 restricted stock units in Spyre Therapeutics. These RSUs vest in two equal installments on September 1, 2026, and September 1, 2027, and each unit converts into one share of common stock if the executive remains employed through each vesting date.

Was the Spyre Therapeutics (SYRE) CFO’s stock sale part of a Rule 10b5-1 plan?

Yes, the CFO’s stock sales were made under a Rule 10b5-1 trading plan. The Form 4 states the transactions were executed pursuant to a trading plan that was adopted on November 10, 2025, providing pre-established instructions for selling shares.